Outcomes must be comprehensive, including cognitive decline (ADAS-Cog), core AD pathology (via Aβ and tau PET imaging), systemic and central inflammatory cytokines, and gut permeability markers (zonulin). The gene discussed is MAPT; the disease is Alzheimer disease.